Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to define and evaluate optical coherence tomography (OCT) stent guidance parameters through prospective data collection in percutaneous coronary intervention (PCI) procedures of de novo lesions.
Optical coherence tomography (OCT) is an imaging modality that uses near-infrared light to produce high resolution, real-time images that are clearer and more quickly produced than those produced by intravascular ultrasound (IVUS). OCT imaging is performed utilizing an imaging catheter with a single optical fiber core that both emits light and records its reflection while simultaneously rotating 360° during continuous pullback within the coronary artery. Fractional Flow Reserve (FFR) is a pressure-derived, lesion-specific, physiological index determining the hemodynamic severity of intracoronary lesions. FFR is measured by placing a pressure guidewire across the lesion of interest and pharmacologically inducing hyperemia. The ratio of distal to proximal pressure allows the physician to physiologically determine if the narrowing is the cause of ischemia. the goal of this study is to define new parameters for stent optimization, benefitting from the unique Fourier-domain (FD-OCT) capabilities.
This stage I study will identify the parameters which will be prospectively tested in a second stage II protocol.
In hospital, 30 day, and 12 month outcomes data will be correlated with OCT baseline findings in order to identify optimal stent implant parameters.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single or multi vessel disease | Pre- and post-PCI fractional flow reserve (FFR) and OCT were performed in participants. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| OCT stent guidance | Device | Participants undergoing pre- and post-PCI fractional flow reserve (FFR) and OCT |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of OCT Peri-procedural Guidance Parameter(s) for Stenting | Incidence of OCT peri-procedural guidance parameter(s) for stenting and their relation to patient outcomes in-hospital. | In-hospital until discharge |
| Incidence of OCT Peri-procedural Guidance Parameter(s) for Stenting | Incidence of OCT peri-procedural guidance parameter(s) for stenting and their relation to patient outcomes through 30 days | 30 Days |
| Incidence of OCT Peri-procedural Guidance Parameter(s) for Stenting (Academic Research Consortium(ARC)) | Incidence of OCT peri-procedural guidance parameter(s) for stenting and their relation to patient outcomes through 12 months | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Change in Physician Decision-making Pre and Post PCI Due to OCT | Assessment of OCT on Physician Decision Making includes:
| 1 Year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Elective or ad hoc PCI, stable angina, acute coronary syndrome
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital - Univ. of Alabama at Birmingham (UAB) | Birmingham | Alabama | 35233 | United States | ||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26242713 | Derived | Wijns W, Shite J, Jones MR, Lee SW, Price MJ, Fabbiocchi F, Barbato E, Akasaka T, Bezerra H, Holmes D. Optical coherence tomography imaging during percutaneous coronary intervention impacts physician decision-making: ILUMIEN I study. Eur Heart J. 2015 Dec 14;36(47):3346-55. doi: 10.1093/eurheartj/ehv367. Epub 2015 Aug 4. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Of the 1069 subjects, 616 were failed to screen and 35 were not qualified for inclusion. Thus 418 subjects underwent pre-intervention fractional flow reserve (FFR) and optical coherence tomography (OCT), percutaneous coronary intervention (PCI), and post intervention FFR and OCT. The subjects were followed up through 12 month post stent implant.
Initially a total of 1069 subjects gave consent from 36 investigational sites, of which 418 qualified subjects completed enrollment in February 2014 at 35 investigational sites. First subject was enrolled on Dec 11, 2012 and the last subject completed the 12 month follow-up on Mar 12, 2015.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Optical Coherence Tomography (OCT) | Participants undergoing PCI with intention to perform FFR and OCT pre and post PCI. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
| Scripps Clinic, Green Hospital |
| La Jolla |
| California |
| United States |
| Florida Hospital Orlando | Orlando | Florida | United States |
| Emory University Hospital | Atlanta | Georgia | United States |
| Loyola University Chicago | Maywood | Illinois | 60153 | United States |
| Central Baptist Hospital | Lexington | Kentucky | United States |
| Baptist Health East | Louisville | Kentucky | United States |
| St. Luke's Hospital/Mid America Heart | Kansas City | Missouri | United States |
| Rutgers Cardiovascular Institute | New Brunswick | New Jersey | United States |
| Mount Sinai Medical Center | New York | New York | United States |
| Heart Hospital of Austin | Austin | Texas | United States |
| Dallas VA Medical Center | Dallas | Texas | United States |
| University of Texas Medical Branch at Galveston | Galveston | Texas | United States |
| Swedish Medical Center | Seattle | Washington | United States |
| Aurora St. Luke's Medical Center | Milwaukee | Wisconsin | United States |
| The Prince Charles Hospital | Chermside | Queensland | Australia |
| Med. Univ. Vienna | Vienna | Austria |
| OLV Hospital | Aalst | Belgium |
| Gasthuisberg Leuven | Leuven | Belgium |
| Montreal Heart Institute | Montreal | Quebec | Canada |
| University of Hong Kong | Hong Kong | Hong Kong | China |
| University Hospital Brno | Brno | Czechia |
| CHU Clermont Ferrand | Clermont-Ferrand | France |
| CHC du Marie Lannelongue | Le Plessis-Robinson | France |
| Clinique Pasteur | Toulouse | France |
| Deutsches Herzzentrum | Munich | Germany |
| Ospedali Riuniti di Bergamo | Bergamo | Italy |
| Centro Cardiologico Monzino | Milan | Italy |
| Ospedale San Giovanni Addolorata | Rome | Italy |
| Kobe University Graduate School of Medicine | Hyōgo | Japan |
| Nara Medical University Hospital | Nara | Japan |
| Osaka Saiseikai Nakatsu Hospital | Osaka | Japan |
| Wakayama Medical University | Wakayama | Japan |
| Thoraxcentre Erasmus MC | Rotterdam | Netherlands |
| Hospital Univ. Clinico San Carlos | Madrid | Spain |
| Royal Brompton Hospital | London | United Kingdom |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Optical Coherence Tomography (OCT) | Participants undergoing PCI with intention to perform FFR and OCT pre and post PCI. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| ||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||||||
| Region of Enrollment | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Incidence of OCT Peri-procedural Guidance Parameter(s) for Stenting | Incidence of OCT peri-procedural guidance parameter(s) for stenting and their relation to patient outcomes in-hospital. | Posted | Number | Percentage of per-subject incidence | In-hospital until discharge |
|
|
| |||||||||||||||||||||||||||||||||||||
| Primary | Incidence of OCT Peri-procedural Guidance Parameter(s) for Stenting | Incidence of OCT peri-procedural guidance parameter(s) for stenting and their relation to patient outcomes through 30 days | Posted | Number | Percentage of per-subject incidence | 30 Days |
|
| ||||||||||||||||||||||||||||||||||||||
| Primary | Incidence of OCT Peri-procedural Guidance Parameter(s) for Stenting (Academic Research Consortium(ARC)) | Incidence of OCT peri-procedural guidance parameter(s) for stenting and their relation to patient outcomes through 12 months | Posted | Number | Percentage of per-subject incidence | 12 months |
|
| ||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Change in Physician Decision-making Pre and Post PCI Due to OCT | Assessment of OCT on Physician Decision Making includes:
| Posted | Number | Percentage of participants | 1 Year |
|
|
1-Year
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Optical Coherence Tomography (OCT) | Participants undergoing PCI with intention to perform FFR and OCT pre and post PCI. | 8 | 418 | 112 | 418 | 128 | 418 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abdominal Pain | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Abnormal Lab Value | Investigations | MedDRA 11.0 | Systematic Assessment |
| |
| Acute Bronchitis | Respiratory, thoracic and mediastinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Acute Erosive Gastritis | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Anemias | Blood and lymphatic system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Angina Pectoris | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Ankle Fracture | Injury, poisoning and procedural complications | MedDRA 11.0 | Systematic Assessment |
| |
| Arterial Hypertension/Hypertension | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Ascites | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Atrial Fibrillation | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Atrial Flutter | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Atrioventricular (AV) Dissociation | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Bleeding | Blood and lymphatic system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 11.0 | Systematic Assessment |
| |
| Cardiac Arrest | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Cardiomyopathy | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Cardiovascular Deconditioning | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Chest Pain | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Cholelithiasis | Hepatobiliary disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Chronic Obstructive Pulmonary Disease (COPD) | Respiratory, thoracic and mediastinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Colon Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 11.0 | Systematic Assessment |
| |
| Colon Polyps | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 11.0 | Systematic Assessment |
| |
| Coronary Artery Disease | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Diabetic Ketoacidosis | Endocrine disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Diarrhea | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Discomfort | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Dyspnea | Respiratory, thoracic and mediastinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| EKG Abnormalities | Investigations | MedDRA 11.0 | Systematic Assessment |
| |
| Echo Finding | Investigations | MedDRA 11.0 | Systematic Assessment |
| |
| Elective Surgery | Surgical and medical procedures | MedDRA 11.0 | Systematic Assessment |
| |
| Emesis/Vomiting | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Gastrointestinal Bleeding | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Gingival Bleeding | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Gout | Musculoskeletal and connective tissue disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Heart Failure | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Hematochezia | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Hematoma | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Hematuria | Renal and urinary disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Hyperkalemia | Investigations | MedDRA 11.0 | Systematic Assessment |
| |
| Hypotension | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Idiopathic Interstitial Lung Diseases | Respiratory, thoracic and mediastinal disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Influenza | Infections and infestations | MedDRA 11.0 | Systematic Assessment |
| |
| Intracerebral Haemorrhage | Nervous system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Ischemic Stroke | Nervous system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Knee Pain | Musculoskeletal and connective tissue disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Left Bundle Branch Block/Complete Left Bundle Branch Block | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Lung Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 11.0 | Systematic Assessment |
| |
| Melena | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Musculoskeletal Pain | Musculoskeletal and connective tissue disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Myocardial Infarction | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Non-Cardiac Chest Pain | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Non-Endpoint Transient Ischemic Attack (TIA) | Nervous system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Other | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Pericardial Tamponade | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Pleural Effusion | Respiratory, thoracic and mediastinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA 11.0 | Systematic Assessment |
| |
| Pneumonia in the Compromised Host | Infections and infestations | MedDRA 11.0 | Systematic Assessment |
| |
| Presyncope | Nervous system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Pulmonary Embolism | Respiratory, thoracic and mediastinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Radiculopathy | Nervous system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Respiratory Failure | Respiratory, thoracic and mediastinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Side Branch Compromise | Injury, poisoning and procedural complications | MedDRA 11.0 | Systematic Assessment |
| |
| Stroke | Nervous system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Syncope | Nervous system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Third Degree Heart Block (Complete Heart Block) | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Unstable Angina | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| VASC Vessel Stenosis | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Ventricular Fibrillation | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Vessel Stenosis | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Visual Disturbance | Eye disorders | MedDRA 11.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abdominal Pain | General disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Abnormal Lab Value | Investigations | MedDRA 11.0 | Systematic Assessment |
| |
| Abrasion | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Acute Bronchitis | Respiratory, thoracic and mediastinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Acute Pancreatitis | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Allergy | Immune system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Anemias | Blood and lymphatic system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Angina Pectoris | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Anxiety | Psychiatric disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Aortic Aneurysms | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Apnea | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Arm Fracture | Musculoskeletal and connective tissue disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Arm Pain | Musculoskeletal and connective tissue disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Arterial Hypertension/Hypertension | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Arteriovenous (AV) Fistula | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Aspiration Pneumonia/Necrotizing Pneumonia/Aspiration of Vomitus | Infections and infestations | MedDRA 11.0 | Systematic Assessment |
| |
| Asthma | Respiratory, thoracic and mediastinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Atrial Fibrillation | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Back Pain | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Bleeding | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Blurred Vision | Eye disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Bruise/Purpura Simplex | Skin and subcutaneous tissue disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Bursitis | Musculoskeletal and connective tissue disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Callus | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 11.0 | Systematic Assessment |
| |
| Carpal Tunnel | Nervous system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Cellulitis | Skin and subcutaneous tissue disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Chest Pain | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Chest Tightness | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Chronic Obstructive Pulmonary Disease (COPD) | Respiratory, thoracic and mediastinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Chronic Renal Failure | Renal and urinary disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Common Cold/Upper Respiratory Tract Infection | Infections and infestations | MedDRA 11.0 | Systematic Assessment |
| |
| Conjunctivitis | Eye disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Cyst | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 11.0 | Systematic Assessment |
| |
| Depression | Psychiatric disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Diarrhea | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Difficulty Catching Breath | Respiratory, thoracic and mediastinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Diverticulitis | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Dizziness | Ear and labyrinth disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Dry Eyes | Eye disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Dyspepsia | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Dysphagia | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Dyspnea | Respiratory, thoracic and mediastinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Dysuria | Renal and urinary disorders | MedDRA 11.0 | Systematic Assessment |
| |
| EKG Abnormalities | Investigations | MedDRA 11.0 | Systematic Assessment |
| |
| Edema | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Eye Infection | Eye disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Fainting/Blackout | Nervous system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Fatigue/Generalized Fatigue | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Fever | Infections and infestations | MedDRA 11.0 | Systematic Assessment |
| |
| Gastroesophageal Reflux Disease | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Gout | Musculoskeletal and connective tissue disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Hematoma | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Hematuria | Renal and urinary disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Hiatus Hernia | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Hip Pain | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Hyperglycemia | Endocrine disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Hypokalemia | Investigations | MedDRA 11.0 | Systematic Assessment |
| |
| Hypokinetic Septal Motion | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Hyponatremia | Investigations | MedDRA 11.0 | Systematic Assessment |
| |
| Ingestion | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Iron-Deficiency Anemia | Blood and lymphatic system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Knee Pain | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Lacerations | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Low Back Pain | Musculoskeletal and connective tissue disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Melena | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Mitral Valve Regurgitation/Mitral Insufficiency | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Muscle Strain | Musculoskeletal and connective tissue disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Musculoskeletal Pain | Musculoskeletal and connective tissue disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Myalgias | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Nausea | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Neck Pain | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Nephrolithiasis | Renal and urinary disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Obstructive Sleep Apnea | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Orthostatic Hypotension | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Other | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Pain | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Palpitations | Cardiac disorders | MedDRA 10.0 | Systematic Assessment |
| |
| Peak T Waves | Investigations | MedDRA 11.0 | Systematic Assessment |
| |
| Pneumonia | Respiratory, thoracic and mediastinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Post-Nasal Drainage | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Premature Ventricular Contraction | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Prostatitis | Reproductive system and breast disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Rash | Skin and subcutaneous tissue disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Renal Artery Stenosis | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Rib Fracture | Injury, poisoning and procedural complications | MedDRA 11.0 | Systematic Assessment |
| |
| Sinus Bradycardia/Sinus Bradycardia (Cardiac Arrhythmia) | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Sinusitis | Respiratory, thoracic and mediastinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Skin Bruise | Skin and subcutaneous tissue disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Skin Lesions | Skin and subcutaneous tissue disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Swelling | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Syncope | Nervous system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Tachycardia | Cardiac disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Thrombus | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Tooth Infection | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Toothache | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Trauma | Injury, poisoning and procedural complications | MedDRA 11.0 | Systematic Assessment |
| |
| Unsustained/Nonsustained Ventricular Tachy/Cardiac Arrhythmia | Cardiac disorders | MedDRA 11.0 | Systematic Assessment | Unsustained/Nonsustained Ventricular Tachy/Cardiac Arrhythmia includes: Other - Non-sustained runs of VT, Ventricular Ectopic Beats/Premature Ventricular Contractions/Premature Ventricular Beats |
|
| Urinary Tract Infections | Renal and urinary disorders | MedDRA 11.0 | Systematic Assessment |
| |
| VASC Bruise | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
| |
| VASC Hematoma | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
| |
| VASC Pseudoaneurysm | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
| |
| VASC Vessel Stenosis | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Vaso Vagal Response | Nervous system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Vertigo | Nervous system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Vessel Stenosis | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Viral Gastroenteritis | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Visual Disturbance | Eye disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Weakness | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| Wrist Sprain | Musculoskeletal and connective tissue disorders | MedDRA 11.0 | Systematic Assessment |
|
Patients with acute STEMI, left main PCI, severe chronic kidney disease, and other high-risk features were excluded. No prescriptive recommendations were provided in the protocol, a wide variation in physician behavior was expected and observed.
Proposals for all publications, abstracts, presentations, or journal manuscripts arising from, or related to the Study will be submitted for approval to the Publications Committee. Accordingly, decisions on timing and content of publications and presentations from the Study will be coordinated with the Study Publication Committee and Sponsor.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Sr. Manager, Global Clinical Affairs | St. Jude Medical | 651-756-5585 | mwagner2@sjm.com |
| ID | Term |
|---|---|
| D003324 | Coronary Artery Disease |
| D020163 | Ornithine Carbamoyltransferase Deficiency Disease |
| ID | Term |
|---|---|
| D003327 | Coronary Disease |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
| D056806 | Urea Cycle Disorders, Inborn |
| D020739 | Brain Diseases, Metabolic, Inborn |
| D001928 | Brain Diseases, Metabolic |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D040181 | Genetic Diseases, X-Linked |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D000592 | Amino Acid Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| Japan |
|
| United Kingdom |
|
| Spain |
|
| Canada |
|
| Austria |
|
| Netherlands |
|
| Belgium |
|
| China |
|
| Italy |
|
| Australia |
|
| France |
|
| Germany |
|
| Title | Measurements |
|---|---|
|
| Device-oriented MACE(TLR) |
|
| Patient-oriented MACE(All-cause mortality) |
|
| Patient-oriented MACE(MI-ARC Definition) |
|
| Patient-oriented MACE(MI-3rd Universal definition) |
|
| Patient-oriented MACE(Any Revascularization) |
|
| Stent Thrombosis(Definite) |
|
| Stent Thrombosis(Probable) |
|
| Stent Thrombosis(Possible) |
|
| Stent Thrombosis(Early) |
|
| Stent Thrombosis(Late) |
|
| Stent Thrombosis(Very Late) |
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
| Device-oriented MACE (Cardiac death) |
| |||||
| Device-oriented MACE(MI-AEC definition) |
| |||||
| Device-oriented MACE(MI-3rd Universal definition) |
| |||||
| Device-oriented MACE(TLR) |
| |||||
| Patient-oriented MACE(All-cause mortality) |
| |||||
| Patient-oriented MACE(MI-ARC Definition) |
| |||||
| Patient-oriented MACE(MI-3rd Universal definition) |
| |||||
| Patient-oriented MACE(Any Revascularization) |
| |||||
| Stent Thrombosis(Definite) |
| |||||
| Stent Thrombosis(Probable) |
| |||||
| Stent Thrombosis(Possible) |
| |||||
| Stent Thrombosis(Early) |
| |||||
| Stent Thrombosis(Late) |
| |||||
| Stent Thrombosis(Very Late) |
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
| Device-oriented MACE (Cardiac death) |
| |||||
| Device-oriented MACE(MI-AEC definition) |
| |||||
| Device-oriented MACE(MI-3rd Universal definition) |
| |||||
| Device-oriented MACE(TLR) |
| |||||
| Patient-oriented MACE(All-cause mortality) |
| |||||
| Patient-oriented MACE(MI-ARC Definition) |
| |||||
| Patient-oriented MACE(MI-3rd Universal definition) |
| |||||
| Patient-oriented MACE(Any Revascularization) |
| |||||
| Stent Thrombosis(Definite) |
| |||||
| Stent Thrombosis(Probable) |
| |||||
| Stent Thrombosis(Possible) |
| |||||
| Stent Thrombosis(Early) |
| |||||
| Stent Thrombosis(Late) |
| |||||
| Stent Thrombosis(Very Late) |
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
| Procedure Planning(Pre-PCI OCT) |
| |||||
| Procedure Planning(Post-PCI OCT) |
| |||||
| Physician decision-making (Pre-PCI OCT) |
| |||||
| Physician decision-making (Post-PCI OCT) |
|